Education
About Us
Working with TipRanks
Follow Us
National Healthcare Corp. (NHC)
:NHC
Top Page
National Healthcare
(NYSE MKT:NHC)
61Neutral
National Healthcare (NHC) vs. S&P 500 (SPY)
Market Cap
$1.44B
Dividend Yield2.61%
Average Volume (3M)69.81K
Price to Earnings (P/E)14.3
Beta (1Y)0.83
Revenue Growth15.25%
EPS Growth51.77%
CountryUS
Employees14,962
SectorHealthcare
Sector Strength78
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)6.54
Shares Outstanding15,461,829
10 Day Avg. Volume83,532
30 Day Avg. Volume69,814
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)N/A
Price to Sales (P/S)1.08
Price to Cash Flow (P/CF)27.40
P/FCF Ratio152.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
National Healthcare Business Overview & Revenue Model
Company DescriptionNational Healthcare (NHC) is a prominent provider in the healthcare sector, offering a comprehensive range of services including skilled nursing, assisted living, and rehabilitation services. NHC operates numerous healthcare centers across the United States, focusing on delivering high-quality patient care and support services tailored to the needs of elderly and disabled individuals.
How the Company Makes MoneyNational Healthcare primarily makes money through the provision of healthcare services at its facilities. The company's revenue streams include payments from private payers, government programs such as Medicare and Medicaid, and private insurance companies. NHC also derives income from ancillary services such as rehabilitation therapy, pharmacy services, and specialized healthcare programs. Strategic partnerships with healthcare providers and insurance companies play a significant role in ensuring a steady flow of patients and optimizing revenue generation.
National Healthcare Financial Statement Overview
Summary
National Healthcare presents a strong financial profile with steady revenue and profit growth. The income statement shows improved margins, although operating efficiency could be enhanced. The balance sheet highlights a solid equity base but with increased leverage. Cash flow indicates stable operational cash generation, albeit with a slight decline in free cash flow. Continued focus on operational efficiency and debt management will be crucial for future growth.Income Statement
National Healthcare has demonstrated strong revenue growth, increasing from approximately $1.14 billion in 2023 to $1.25 billion in 2024, a growth rate of 9.66%. The gross profit margin remains solid at 35.22% for 2024. The net profit margin improved significantly from 5.85% in 2023 to 8.14% in 2024, reflecting enhanced profitability. However, the EBIT margin is relatively low at 6.85%, and the EBITDA margin is 8.75%, indicating room for operational efficiency improvements.78
Positive
Balance Sheet
The company's debt-to-equity ratio increased to 0.22 in 2024 from 0.10 in 2023, which may indicate higher leverage risk. Return on equity improved to 10.40% in 2024 compared to 7.35% in 2023, reflecting better profitability from shareholders' equity. The equity ratio decreased slightly to 0.74 in 2023 from 0.69 in 2022, showing a stable financial position despite increased liabilities.72
Positive
Cash Flow
The free cash flow decreased slightly by 4.33% in 2024 compared to 2023. The operating cash flow to net income ratio was stable at 1.05, suggesting efficient conversion of income into cash. However, the free cash flow to net income ratio decreased to 0.78, indicating reduced cash generation relative to profits.65
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.30B | 1.14B | 1.07B | 1.01B | 980.71M | Gross Profit |
| 487.01M | 429.20M | 388.11M | 344.88M | 371.41M | EBIT |
| 85.76M | 57.13M | 31.90M | 50.92M | 48.16M | EBITDA |
| 182.53M | 131.10M | 68.28M | 191.56M | 95.84M | Net Income Common Stockholders |
| 101.93M | 66.80M | 22.45M | 138.59M | 41.87M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 216.19M | 223.62M | 182.59M | 256.02M | 323.44M | Total Assets |
| 1.52B | 1.31B | 1.28B | 1.40B | 1.36B | Total Debt |
| 214.77M | 93.39M | 125.94M | 166.66M | 194.02M | Net Debt |
| 138.65M | -13.69M | 67.27M | 59.05M | 46.92M | Total Liabilities |
| 541.27M | 400.32M | 397.94M | 500.39M | 566.96M | Stockholders Equity |
| 980.16M | 908.75M | 874.28M | 903.00M | 795.18M |
| Cash Flow | Free Cash Flow | |||
| 79.70M | 83.31M | -21.46M | 23.00M | 181.39M | Operating Cash Flow |
| 107.30M | 111.22M | 8.74M | 62.39M | 203.26M | Investing Cash Flow |
| -236.69M | -17.57M | -5.98M | -65.89M | -63.88M | Financing Cash Flow |
| 100.34M | -42.55M | -47.64M | -35.26M | -41.89M |
National Healthcare Technical Analysis
Neutral
92.89
Price Trends
95.29
Negative
105.24
Negative
112.99
Negative
Market Momentum
-0.93
Negative
50.89
Neutral
63.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NHC, the sentiment is Neutral. The current price of 92.89 is above the 20-day moving average (MA) of 92.33, below the 50-day MA of 95.29, and below the 200-day MA of 112.99, indicating a neutral trend. The MACD of -0.93 indicates Negative momentum. The RSI at 50.89 is Neutral, neither overbought nor oversold. The STOCH value of 63.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NHC.
National Healthcare Risk Analysis
National Healthcare disclosed 31 risk factors in its most recent earnings report. National Healthcare reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
National Healthcare Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $12.27B | 11.22 | 17.82% | 0.42% | 10.82% | 65.64% | |
73 Outperform | $85.96B | 15.87 | -230.22% | 0.77% | 8.67% | 15.32% | |
72 Outperform | $12.64B | 4.12 | 110.75% | ― | 0.57% | 440.71% | |
61 Neutral | $1.44B | 14.28 | 10.79% | 2.61% | 15.25% | 51.77% | |
61 Neutral | $2.64B | 10.22 | 8.73% | ― | 7.69% | ― | |
52 Neutral | $355.19M | ― | 39.18% | ― | 1.16% | -278.41% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% |
* Healthcare Sector Average
Performance Comparison
NHC
National Healthcare
92.89
2.39
2.64%
ACHC
Acadia Healthcare
27.37
-48.60
-63.97%
CYH
Community Health
2.53
-0.65
-20.44%
HCA
HCA Healthcare
349.14
22.96
7.04%
THC
Tenet Healthcare
120.35
18.17
17.78%
UHS
Universal Health
174.53
1.80
1.04%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.